無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のワクチン市場・予測

Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, End User, Companies

発行 Renub Research 商品コード 543298
出版日 ページ情報 英文 355 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.52円で換算しております。
Back to Top
世界のワクチン市場・予測 Global Vaccine Market, People Vaccinated, Administered, Immunization, By Disease, End User, Companies
出版日: 2018年06月14日 ページ情報: 英文 355 Pages
概要

当レポートでは、世界のワクチン市場について調査分析し、成人・小児用ワクチン市場の分析と予測、予防接種人口の分析と予測、疾患別によるワクチン投与量の分析と予測、および主要企業のプロファイルなどをまとめています。

第1章 調査結果

第2章 世界のワクチン市場・予測

  • 成人用ワクチン市場・予測
  • 小児用ワクチン市場・予測

第3章 世界の成人用ワクチン vs. 小児用ワクチン市場シェア

第4章 世界のワクチン市場シェア・予測

  • 成人用ワクチン市場シェア・予測
  • 小児用ワクチン市場シェア・予測

第5章 世界の予防接種人口・予測

  • 成人予防接種人口・予測
  • 小児予防接種人口・予測

第6章 世界の予防接種人口シェア・予測

  • 成人予防接種人口シェア・予測
  • 小児予防接種人口シェア・予測

第7章 世界のワクチン投与量・予測

  • 成人用ワクチン投与量・予測
  • 小児用ワクチン投与量・予測

第8章 世界のワクチン投与量シェア・予測

  • 成人用ワクチン投与量シェア・予測
  • 小児用ワクチン投与量シェア・予測

第9章 世界のワクチン企業の市場シェア・予測

第10章 疾患別によるワクチン市場・予測

  • インフルエンザ
  • 子宮頸癌 (HPV):ワクチン市場・予測
  • 帯状疱疹:ワクチン市場・予測
  • MMRV・MMR (麻しん、流行性耳下腺炎、風疹、および水痘ワクチン) :ワクチン市場・予測
  • 肺炎球菌:ワクチン市場・予測
  • 髄膜炎:ワクチン市場・予測
  • 肝炎:ワクチン市場・予測
  • TdaP・DTaP (破傷風、ジフテリア、百日咳) :ワクチン市場・予測
  • インフルエンザB型:ワクチン市場・予測
  • 併用ワクチン:ワクチン市場・予測
  • ポリオ:ワクチン市場・予測
  • ロタウィルス:ワクチン市場・予測
  • 水痘:ワクチン市場・予測

第11章 疾患別による予防接種者数・予測

第12章 疾患別によるワクチン投与量・予測

第13章 疾患別による予防接種プロファイル

  • 乳児の予防接種率
  • 世界の予防接種プロファイル
  • 地域の予防接種プロファイル

第14章 ワクチン主要企業の売上・予測

  • GlaxoSmithKline, plc.:ワクチン売上・予測
  • Merck & Co.:ワクチン売上・予測
  • Sanofi Pasteur:ワクチン売上・予測
  • Pfizer, Inc.:ワクチン売上・予測
  • その他のワクチン売上・予測

第15章 ワクチン:製品・パイプライン

  • GSK
  • Merck
  • Sanofi
  • Pfizer

第16章 ワクチン産業における主なM&A

第17章 ワクチンおよび規制当局の介入

第18章 ワクチン市場の促進因子

第19章 ワクチン市場の課題

目次

Global Vaccine Market is projected to reach US$ 70 Billion by the year 2024. The vaccine market is likely to witness a significant growth throughout the forecast period due to the growing prevalence of diseases, increasing government and non-government funding for vaccine development & distribution and increasing investments by companies to develop new vaccines. Furthermore, growing demand for preventive vaccines, rising consciousness about vaccination coupled with mounting demand from the emerging countries is expected to boost the global vaccine businesses in the near future.

The vaccine is a safe and effective biological preparation, which improves the immunity against a particular disease. Technological advancement, rising demand for low cost products and widespread routine immunization programmes in several countries around the world will certainly expect to stimulate the growth of the vaccine market in the following years. Also, rising demand for combinations vaccines as it provides immunization against several diseases in a single shot is further expected to boost the vaccine business growth.

Renub Research report titled “Global Vaccine Market, People Vaccinated, Vaccines Administered, Immunization, By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, Combination Vaccine, Travel & Miscellaneous Vaccine], By End User [Infants (Pediatric), & Adult], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at noteworthy rate over the coming years

The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Haemophilus influenzae type B (Hib), Polio, Rotavirus, Varicella, Combination Vaccine, Travel & Miscellaneous Vaccine. Influenza, Pneumococcal, Meningococcal, Hepatitis and Combination Vaccines together hold the significant market share and is expected to continue so.

By End User - Infants (Pediatric) Segment leads the Global Vaccine Market

The report studies the market by end user as Infants (Pediatric) and Adults. It is found that the market for Infants (Pediatric) segment is huge because as most of the countries now have included a series of vaccines to their National Immunization Programme as the per WHO recommendations. For the year 2017; Combos (Combination Vaccines) has the maximum immunization share among all pediatric vaccines (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Haemophilus Influenzae Type b(Hib), Polio, Rotavirus, Varicella) studied in the report as they protect against more ailments in single shot, people preferring to get combination vaccine instead of a specific vaccine.

Company Analysis

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently in vaccine business globally. These companies have been studied thoroughly in the report.

Administration of Vaccine Doses

Our analysis found that there is a consistent surge in the number of Pneumococcal and Meningococcal vaccine doses administration in future due to the rising concern against the life-threatening vaccine-preventable diseases around the world.

By Disease:

  • Influenza
  • Cervical Cancer
  • Zoster (Shingles)
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Haemophilus influenzae type B
  • Polio
  • Rotavirus
  • Varicella
  • Combination Vaccine
  • Travel & Miscellaneous Vaccine

By End User:

  • Infants (Pediatric)
  • Adults

Client can purchase this report in sections through Purchase by Chapter Tab given above

Key Companies Covered in the Report:

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer

Global Vaccine Market has been extensively studied from 3 major points, and further sub-divided into 2 more points:

1. World Vaccines (Disease wise) Market & Forecast

  • a. Adult Vaccines Market
  • b. Pediatrics Vaccines Market

2. Number of Vaccinated People (Disease wise) & Forecast

  • a. Number of Vaccinated Adult
  • b. Number of Vaccinated Infants (Pediatric)

3. Doses of Vaccines Administered (Disease wise) & Forecast

  • a. Doses of vaccines administered in Adults
  • b. Doses of vaccines administered in Infants (Pediatric)

Table of Contents

1. Research Findings

2. Global-Vaccines Market and Forecast

  • 2.1. Adult Vaccines Market
  • 2.2. Pediatric (Infant) Vaccines Market

3. Global-Adult Vaccine vs. Pediatric Vaccine Market Share

4. Global-Vaccines Market Share and Forecast

  • 4.1. Adult Vaccines Market Share
  • 4.2. Pediatric (Infant) Vaccines Market Share

5. Global-Vaccinated People

  • 5.1. Adult Immunized and Forecast
  • 5.2. Vaccinated Infant (Pediatric)

6. Global-Vaccinated People Share

  • 6.1. Vaccinated Adult Share
  • 6.2. Vaccinated Infant (Pediatric) Share

7. Global-Doses of Vaccines Administered and Forecast

  • 7.1. Doses of Adult Vaccines Administered
  • 7.2. Doses of Infant (Pediatric) Vaccines Administered

8. Global-Doses of Vaccines Administered Share

  • 8.1. Doses of Vaccines Administered to Adult Share
  • 8.2. Doses of Vaccines Administered to Infant (Pediatric) Share

9. Global-Vaccine Companies Market Share and Forecast

10. Disease wise-Vaccines Market and Forecast

  • 10.1. Influenza-Total Vaccines Market
    • 10.1.1. Influenza-Adult Vaccines Market
    • 10.1.2. Influenza-Pediatric (Infant) Vaccines Market
  • 10.2. Cervical Cancer (HPV)-Vaccines Market
  • 10.3. Zoster (Shingles)-Vaccines Market
  • 10.4. MMR (Measles, Mumps, and Rubella Vaccine)-Total Vaccines Market
    • 10.4.1. MMR-Adult Vaccines Market
    • 10.4.2. MMR-Pediatric (Infant) Vaccines Market
  • 10.5. Pneumococcal-Total Vaccines Market
    • 10.5.1. Pneumococcal-Adult Vaccines Market
    • 10.5.2. Pneumococcal-Pediatric (Infant) Vaccines Market
  • 10.6. Meningococcal-Total Vaccines Market
    • 10.6.1. Meningococcal-Adult Vaccines Market
    • 10.6.2. Meningococcal-Pediatric (Infant) Vaccines Market
  • 10.7. Hepatitis-Total Vaccines Market
    • 10.7.1. Hepatitis-Adult Vaccines Market
    • 10.7.2. Hepatitis-Pediatric (Infant) Vaccines Market
  • 10.8. TdaP and DTaP-Total Vaccines Market
    • 10.8.1. TdaP-Adult Vaccines Market
    • 10.8.2. DTaP-Pediatric (Infant) Vaccines Market
  • 10.9. Travel and Miscellaneous-Vaccines Market
  • 10.10. Haemophilus Influenzae Type B (HIB)-Vaccines Market
  • 10.11. Combos (Combination)-Vaccines Market
  • 10.12. Polio-Vaccines Market
  • 10.13. Rotavirus-Vaccines Market
  • 10.14. Varicella-Vaccines Market
    • 10.14.1. Varicella-Adult Vaccines Market
    • 10.14.2. Varicella-Pediatric (Infant) Vaccines Market

11. Disease wise-Numbers of Vaccinated People & Forecast

  • 11.1. Influenza-Total Number of Vaccinated People
    • 11.1.1. Influenza-Number of Vaccinated Adults
    • 11.1.2. Influenza-Number of Vaccinated Infants
  • 11.2. Cervical Cancer (HPV)-Number of Vaccinated People
  • 11.3. Zoster (Shingles)-Number of Vaccinated People
  • 11.4. MMR-Total Number of Vaccinated People
    • 11.4.1. MMR-Number of Vaccinated Adults
    • 11.4.2. MMR-Number of Vaccinated Infants (Pediatric)
  • 11.5. Pneumococcal-Total Number of Vaccinated People
    • 11.5.1. Pneumococcal-Number of Vaccinated Adults
    • 11.5.2. Pneumococcal-Number of Vaccinated Infants
  • 11.6. Meningococcal-Total Number of Vaccinated People
    • 11.6.1. Meningococcal-Number of Vaccinated Adults
    • 11.6.2. Meningococcal-Number of Vaccinated Infants
  • 11.7. Hepatitis-Total Number of Vaccinated People
    • 11.7.1. Hepatitis-Number of Vaccinated Adults
    • 11.7.2. Hepatitis-Number of Vaccinated Infants
  • 11.8. TdaP and DTaP-Total Number of Vaccinated People
    • 11.8.1. TdaP-Number of Vaccinated Adults
    • 11.8.2. DTaP-Number of Vaccinated Infants
  • 11.9. Hib (Haemophilus Influenzae Type B)-Number of Vaaccinated Infants
  • 11.10. Combos (Combination Vaccines)-Number of Vaccinated Infants
  • 11.11. Polio-Number of Infants Immunized and Forecast
  • 11.12. Rotavirus-Number of Vaccinated Infants
  • 11.13. Varicella-Total Number of Vaccinated People
    • 11.13.1. Varicella-Number of Vaccinated Adults
    • 11.13.2. Varicella-Number of Vaccinated Infants

12. Disease wise-Doses of Vaccines Administered and Forecast

  • 12.1. Influenza-Doses of Vaccines Administered
    • 12.1.1. Influenza-Doses of Adult Vaccines Administered
    • 12.1.2. Influenza-Doses of Infant Vaccines Administered
  • 12.2. Cervical Cancer (HPV)-Doses of Vaccines Administered
  • 12.3. Zoster (Shingles)-Doses of Vaccines Administered
  • 12.4. MMR-Doses of Vaccines Administered
    • 12.4.1. MMR-Doses of Adult Vaccines Administered
    • 12.4.2. MMR-Doses of Infant Vaccines Administered
  • 12.5. Pneumococcal-Doses of Vaccines Administered
    • 12.5.1. Pneumococcal-Doses of Adult Vaccines Administered
    • 12.5.2. Pneumococcal-Doses of Infant Vaccines Administered and Forecast
  • 12.6. Meningococcal-Doses of Vaccines Administered
    • 12.6.1. Meningococcal-Doses of Adult Vaccines Administered
    • 12.6.2. Meningococcal-Doses of Infant Vaccines Administered
  • 12.7. Hepatitis-Doses of Vaccines Administered
    • 12.7.1. Hepatitis-Doses of Adult Vaccines Administered
    • 12.7.2. Hepatitis-Doses of Infant Vaccines Administered
  • 12.8. TdaP and DTaP-Doses of Vaccines Administered
    • 12.8.1. TdaP-Doses of Adult Vaccines Administered and Forecast
    • 12.8.2. DTaP-Doses of Infant Vaccines Administered
  • 12.9. Hib (Haemophilus Influenzae Type B)-Doses of Infant Vaccines Administered and Forecast
  • 12.10. Polio-Doses of Infant Vaccines Administered
  • 12.11. Rotavirus-Doses of Infant Vaccines Administered and Forecast
  • 12.12. Varicella-Doses of Vaccines Administered
    • 12.12.1. Varicella-Doses of Adult Vaccines Administered
    • 12.12.2. Varicella-Doses of Infant Vaccines Administered

13. Disease wise-Immunization Profile

  • 13.1. Immunization Coverage (%) in Infants
  • 13.2. Global Immunization Profile
  • 13.3. Regional Immunization Profile
    • 13.3.1. Measles-Number of Reported Cases
    • 13.3.2. Mumps-Number of Reported Cases
    • 13.3.3. Rubella-Number of Reported Cases
    • 13.3.4. Rubella (CRS)-Number of Reported Cases
    • 13.3.5. Diphtheria-Number of Reported Cases
    • 13.3.6. Tetanus (Neonatal)-Number of Reported Cases
    • 13.3.7. Tetanus (Total)-Number of Reported Cases
    • 13.3.8. Pertussis-Number of Reported Cases
    • 13.3.9. Polio-Number of Reported Cases
    • 13.3.10. Yellow Fever-Number of Reported Cases
    • 13.3.11. Japanese encephalitis-Number of Reported Cases

14. Vaccines Key Players Sales and Forecast

  • 14.1. GlaxoSmithKline, plc.'s Vaccines Sales
  • 14.2. Merck & Co. Vaccines Sales
  • 14.3. Sanofi Pasteur's Vaccines Sales
  • 14.4. Pfizer, Inc.'s Vaccines Sales
  • 14.5. Global-Other Companies Vaccines Sales

15. Vaccines-Products and Pipeline

  • 15.1. GSK Vaccine Product Pipeline
  • 15.2. Merck Vaccine Product Pipeline
  • 15.3. Sanofi Vaccine Product Pipeline
  • 15.4. Pfizer Vaccine Product Pipeline

16. Top Mergers and Acquisitions in the Vaccine Industry

17. Vaccines and Regulator's Interventions

  • 17.1. Making and Meeting Standards of Quality and Safety
  • 17.2. Vaccine Funding

18. Vaccine Market Drivers

  • 18.1. Inclusion in National Immunization Schedule
  • 18.2. Growing Immunization Coverage for HPV Vaccines
  • 18.3. Increase in Prevalence of Infectious Diseases
  • 18.4. Global Immunization Vision and Strategy (GIVS)
  • 18.5. GAVI Model Fuelling Vaccine Manufacturers
    • 18.5.1. The Partnership Model
    • 18.5.2. The Business Model
  • 18.6. Increasing Vaccine Availability in United States
  • 18.7. The Vaccine Safety Data link Project
  • 18.8. The Vaccine Injury Compensation Program
  • 18.9. Transforming of Vaccine Technologies
  • 18.10. Global Vaccine Action Plan by WHO (2011-2020)
  • 18.11. Continuous Focus on Effective Communication Strategies

19. Vaccines Market Challenges

  • 19.1. Hurdles to Optimal use of Licensed Vaccines
    • 19.1.1. Technical Obstacles
    • 19.1.2. Economic Obstacles
    • 19.1.3. Cultural Obstacles
  • 19.2. Complexity of Vaccine Development & Approval System Thwarts Product Development
    • 19.2.1. Legal Obstacles
    • 19.2.2. General Technical Barriers
    • 19.2.3. Economic Barriers
    • 19.2.4. Regulatory Barriers
  • 19.3. Shortening the Timeline for Vaccine Development
  • 19.4. Refusal/Resistance to Vaccination
    • 19.4.1. Vaccine Adverse Event Reporting System
  • 19.5. Vaccine Shortages and Delays
  • 19.6. Obstacles in Vaccine Research & Development
  • 19.7. Barriers to New Entrants in the Vaccines Market

List of Figures:

  • Figure 2-1: Global-Vaccines Market (Billion US$), 2011-2017
  • Figure 2-2: Global-Forecast for Vaccines Market (Billion US$), 2018-2024
  • Figure 2-3: Global-Adult Vaccines Market (Billion US$), 2011-2017
  • Figure 2-4: Global-Forecast for Adult Vaccines Market (Billion US$), 2018-2024
  • Figure 2-5: Global-Pediatric (Infant) Vaccines Market (Billion US$), 2011-2017
  • Figure 2-6: Global-Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018-2024
  • Figure 3-1: Global-Adult Vs. Pediatric Vaccine Market Share, 2011- 2017
  • Figure 3-2: Global-Forecast for Adult Vs. Pediatric Vaccine Market Share, 2018-2024
  • Figure 4-1: Global-Vaccines Market Share (Percent), 2011-2017
  • Figure 4-2: Global-Forecast for Vaccines Market Share (Percent), 2018-2024
  • Figure 4-3: Global-Adult Vaccines Market Share (Percent), 2011-2017
  • Figure 4-4: Global-Forecast for Adult Vaccines Market Share (Percent), 2018-2024
  • Figure 4-5: Global-Pediatric (Infant) Vaccines Market Share (Percent), 2011-2017
  • Figure 4-6: Global-Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2018-2024
  • Figure 5-1: Global-Vaccinated People (Million), 2011-2017
  • Figure 5-2: Global-Forecast for Vaccinated People (Million), 2018-2024
  • Figure 5-3: Global-Number of Vaccinated Adult (Million), 2011-2017
  • Figure 5-4: Global-Forecast for Number of Vaccinated Adult (Million), 2018-2024
  • Figure 5-5: Global-Number of Vaccinated Infant (Pediatric) (Million), 2011-2017
  • Figure 5-6: Global-Forecast for Number of Vaccinated Infant (Pediatric) (Million), 2018-2024
  • Figure 6-1: Global-Vaccinated Adult Share (Percent), 2011-2017
  • Figure 6-2: Global-Forecast for Vaccinated Adult Share (Percent), 2018-2024
  • Figure 6-3: Global-Vaccinated Infant (Pediatric) Share (Percent), 2011-2017
  • Figure 6-4: Global-Forecast for Vaccinated Infant (Pediatric) Share (Percent), 2018-2024
  • Figure 7-1: Global-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 7-2: Global-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 7-3: Global-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 7-4: Global-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 7-5: Global-Doses of Pediatric (Infant) Vaccines Administered (Million), 2011-2017
  • Figure 7-6: Global-Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2018-2024
  • Figure 8-1: Global-Doses of Vaccines Administered Share (Percent), 2011-2017
  • Figure 8-2: Global-Forecast for Doses of Vaccines Administered Share (Percent), 2018-2024
  • Figure 8-3: Global-Doses of Vaccines Administered to Adult Share (Percent), 2011-2017
  • Figure 8-4: Global-Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018-2024
  • Figure 8-5: Global-Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011-2017
  • Figure 8-6: Global-Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2018-2024
  • Figure 9-1: Global-Key Players Vaccines Market Share (Percent), 2011-2017
  • Figure 9-2: Global-Forecast for Key Players Vaccines Market Share (Percent), 2018-2024
  • Figure 10-1: Influenza-Total Vaccines Market (Billion US$), 2011-2017
  • Figure 10-2: Influenza-Forecast for Total Vaccines Market (Billion US$), 2018-2024
  • Figure 10-3: Influenza-Adult Vaccines Market (Billion US$), 2011-2017
  • Figure 10-4: Influenza-Forecast for Adult Vaccines Market (Billion US$), 2018-2024
  • Figure 10-5: Influenza-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-6: Influenza-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 10-7: Cervical Cancer (HPV)-Vaccines Market (Billion US$), 2011-2017
  • Figure 10-8: Cervical Cancer (HPV)-Forecast for Vaccines Market (Billion US$), 2018-2024
  • Figure 10-9: Zoster (Shingles)-Vaccines Market (Billion US$), 2011-2017
  • Figure 10-10: Zoster (Shingles)-Forecast for Vaccines Market (Billion US$), 2018-2024
  • Figure 10-11: MMR-Total Vaccines Market (Billion US$), 2011-2017
  • Figure 10-12: MMR-Forecast for Total Vaccines Market (Billion US$), 2018-2024
  • Figure 10-13: MMR-Adult Vaccines Market (Million US$), 2011-2017
  • Figure 10-14: MMR-Forecast for Adult Vaccines Market (Million US$), 2018-2024
  • Figure 10-15: MMR-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-16: MMR-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 10-17: Pneumococcal-Total Vaccines Market (Billion US$), 2011-2017
  • Figure 10-18: Pneumococcal-Forecast for Total Vaccines Market (Billion US$), 2018-2024
  • Figure 10-19: Pneumococcal-Adult Vaccines Market (Billion US$), 2011-2017
  • Figure 10-20: Pneumococcal-Forecast for Adult Vaccines Market (Billion US$), 2018-2024
  • Figure 10-21: Pneumococcal-Pediatric (Infant) Vaccines Market (Billion US$), 2011-2017
  • Figure 10-22: Pneumococcal-Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2018-2024
  • Figure 10-23: Areas with frequent epidemics of meningococcal meningitis
  • Figure 10-24: Meningococcal-Total Vaccines Market (Million US$), 2011-2017
  • Figure 10-25: Meningococcal-Forecast for Total Vaccines Market (Million US$), 2018-2024
  • Figure 10-26: Meningococcal-Adult Vaccines Market (Million US$), 2011-2017
  • Figure 10-27: Meningococcal-Forecast for Adult Vaccines Market (Million US$), 2018-2024
  • Figure 10-28: Meningococcal-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-29: Meningococcal-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 10-30: Hepatitis-Total Vaccines Market (Billion US$), 2011-2017
  • Figure 10-31: Hepatitis-Forecast for Total Vaccines Market (Billion US$), 2018-2024
  • Figure 10-32: Hepatitis-Adult Vaccines Market (Billion US$), 2011-2017
  • Figure 10-33: Hepatitis-Forecast for Adult Vaccines Market (Billion US$), 2018-2024
  • Figure 10-34: Hepatitis-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-35: Hepatitis-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 10-36: TdaP and DTaP-Total Vaccines Market (Million US$), 2011-2017
  • Figure 10-37: TdaP and DTaP-Forecast for Total Vaccines Market (Million US$), 2018-2024
  • Figure 10-38: TdaP-Adult Vaccines Market (Million US$), 2011-2017
  • Figure 10-39: TdaP-Forecast for Adult Vaccines Market (Million US$), 2018-2024
  • Figure 10-40: DTaP-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-41: DTaP-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 10-42: Travel and Miscellaneous-Vaccines Market (Billion US$), 2011-2017
  • Figure 10-43: Travel and Miscellaneous-Forecast for Vaccines Market (Billion US$), 2018-2024
  • Figure 10-44: Haemophilus Influenzae Type B (HIB)-Vaccines Market (Million US$), 2011-2017
  • Figure 10-45: Haemophilus Influenzae Type B (HIB)-Forecast for Vaccines Market (Million US$), 2018-2024
  • Figure 10-46: Combos (Combination)-Vaccines Market (Billion US$), 2011-2017
  • Figure 10-47: Combos (Combination)-Forecast for Vaccines Market (Billion US$), 2018-2024
  • Figure 10-48: Polio-Vaccines Market (Million US$), 2011-2017
  • Figure 10-49: Polio-Forecast for Vaccines Market (Million US$), 2018-2024
  • Figure 10-50: Rotavirus Deaths Under Five Years of Age per 100 000 Population <5 Years of Age, 2013
  • Figure 10-51: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
  • Figure 10-52: Rotavirus-Vaccines Market (Million US$), 2011-2017
  • Figure 10-53: Rotavirus-Forecast for Vaccines Market (Million US$), 2018-2024
  • Figure 10-54: Varicella-Total Vaccines Market (Billion US$), 2011-2017
  • Figure 10-55: Varicella-Forecast for Total Vaccines Market (Billion US$), 2018-2024
  • Figure 10-38: Varicella-Adult Vaccines Market (Million US$), 2011-2017
  • Figure 10-39: Varicella-Forecast for Adult Vaccines Market (Million US$), 2018-2024
  • Figure 10-40: Varicella-Pediatric (Infant) Vaccines Market (Million US$), 2011-2017
  • Figure 10-41: Varicella-Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2018-2024
  • Figure 11-1: Influenza-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-2: Influenza-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-3: Influenza-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-4: Influenza-Forecast for Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-5: Influenza-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-6: Influenza-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-7: Cervical Cancer-Number of Vaccinated People (Million), 2011-2017
  • Figure 11-8: Cervical Cancer-Forecast for Number of Vaccinated People (Million), 2018-2024
  • Figure 11-9: Zoster (Shingles)-Number of Vaccinated People (Million), 2011-2017
  • Figure 11-10: Zoster (Shingles)-Forecast for Number of Vaccinated People (Million), 2018-2024
  • Figure 11-11: MMR-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-12: MMR-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-13: MMR-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-14: MMR-Forecast for Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-15: MMR-Number of Vaccinated Infants (Pediatric) (Million), 2011-2017
  • Figure 11-16: MMR-Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2018-2024
  • Figure 11-17: Pneumococcal-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-18: Pneumococcal-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-19: Pneumococcal-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-20: Pneumococcal-Forecast for Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-21: Pneumococcal-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-22: Pneumococcal-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-23: Meningococcal-Total Number of People Immunized (Million), 2011-2017
  • Figure 11-24: Meningococcal-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-25: Meningococcal-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-26: Meningococcal-Forecast for Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-27: Meningococcal-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-28: Meningococcal-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-29: Hepatitis-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-30: Hepatitis-Forecast for Total Number of vaccinated People (Million), 2018-2024
  • Figure 11-31: Hepatitis-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-32: Hepatitis-Forecast for Number of Adults Immunized (Thousand), 2018-2024
  • Figure 11-33: Hepatitis-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-34: Hepatitis-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-35: TdaP and DTaP-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-36: TdaP and DTaP-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-37: TdaP-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-38: TdaP-Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-39: DTaP-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-40: DTaP-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-41: Hib (Haemophilus Influenzae Type B)-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-42: Hib (Haemophilus Influenzae Type B)-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-43: Combos (Combination Vaccines)-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-44: Combos (Combination Vaccines)-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-45: Polio-Number of Infants Immunized (Million), 2011-2017
  • Figure 11-46: Polio-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 11-47: Rotavirus-Number of Infants Immunized (Million), 2011-2017
  • Figure 11-48: Rotavirus-Forecast for Number of Infants Immunized (Million), 2018-2024
  • Figure 11-35: Varicella-Total Number of Vaccinated People (Million), 2011-2017
  • Figure 11-36: Varicella-Forecast for Total Number of Vaccinated People (Million), 2018-2024
  • Figure 11-37: Varicella-Number of Vaccinated Adults (Million), 2011-2017
  • Figure 11-38: Varicella-Number of Vaccinated Adults (Million), 2018-2024
  • Figure 11-39: Varicella-Number of Vaccinated Infants (Million), 2011-2017
  • Figure 11-40: Varicella-Forecast for Number of Vaccinated Infants (Million), 2018-2024
  • Figure 12-1: Influenza-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-2: Influenza-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-3: Influenza-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-4: Influenza-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-5: Influenza-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-6: Influenza-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-7: Cervical Cancer (HPV)-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-8: Cervical Cancer (HPV)-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-9: Zoster (Shingles)-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-10: Zoster (Shingles)-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-11: MMR-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-12: MMR-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-13: MMRV-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-14: MMRV-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-15: MMR-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-16: MMR-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-17: Pneumococcal-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-18: Pneumococcal-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-19: Pneumococcal-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-20: Pneumococcal-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-21: Pneumococcal-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-22: Pneumococcal-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-23: Meningococcal-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-24: Meningococcal-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-25: Meningococcal-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-26: Meningococcal-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-27: Meningococcal-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-28: Meningococcal-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-29: Hepatitis-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-30: Hepatitis-Forecast for Doses of Vaccines Administered (Million), 2018-2024
  • Figure 12-31: Hepatitis-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-32: Hepatitis-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-33: Hepatitis-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-34: Hepatitis-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-35: TdaP and DTaP-Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-36: TdaP and DTaP-Forecast for Doses of Vaccines Administered (million), 2018-2024
  • Figure 12-37: TdaP-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-38: TdaP-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-39: DTaP-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-40: DTaP-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-41: Hib (Haemophilus Influenzae Type B)-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-42: Hib (Haemophilus Influenzae Type B)-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-43: Polio-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-44: Polio-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-45: Rotavirus-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-46: Rotavirus-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 12-35: Varicella-Total Doses of Vaccines Administered (Million), 2011-2017
  • Figure 12-36: Varicella-Forecast for Total Doses of Vaccines Administered (million), 2018-2024
  • Figure 12-37: Varicella-Doses of Adult Vaccines Administered (Million), 2011-2017
  • Figure 12-38: Varicella-Forecast for Doses of Adult Vaccines Administered (Million), 2018-2024
  • Figure 12-47: Varicella-Doses of Infant Vaccines Administered (Million), 2011-2017
  • Figure 12-48: Varicella-Forecast for Doses of Infant Vaccines Administered (Million), 2018-2024
  • Figure 14-1: Global-GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2011-2017
  • Figure 14-2: Global-Forecast for GlaxoSmithKline, plc.'s Vaccines Sales (Billion US$), 2018-2024
  • Figure 14-3: Global-Merck & Co. Vaccines Sales (Billion US$), 2011-2017
  • Figure 14-4: Global-Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018-2024
  • Figure 14-5: Global-Sanofi Pasteur's Vaccines Sales (Billion US$), 2011-2017
  • Figure 14-6: Global-Forecast for Sanofi Pasteur's Vaccines Sales (Billion US$), 2018-2024
  • Figure 14-7: Global-Pfizer, Inc.'s Vaccines Sales (Billion US$), 2011-2017
  • Figure 14-8: Global-Forecast for Pfizer, Inc.'s Vaccines Sales (Billion US$), 2018-2024
  • Figure 14-9: Global-Other Companies Vaccines Sales (Billion US$), 2011-2017
  • Figure 14-10: Global-Forecast for Other Companies Vaccines Sales (Billion US$), 2018-2024
  • Figure 15-1: GSK Vaccine Product Pipeline
  • Figure 18-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
  • Figure 18-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
  • Figure 18-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 18-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
  • Figure 18-5: US Retail Clinics Expected to Surge by 2017

Lists of Tables:

  • Table 2-1: Vaccine Recommendations
  • Table 2-2: Other Recommended Vaccines
  • Table 6-1: Global-Vaccinated People Share (Percent), 2011-2017
  • Table 6-2: Global-Forecast for Vaccinated People Share (Percent), 2018-2024
  • Table 13-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
  • Table 13-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
  • Table 13-3: Vaccines-Number of Reported Cases, 2011-2017
  • Table 13-4: Measles-Number of Reported Cases, 2001-2016
  • Table 13-5: Mumps-Number of Reported Cases, 2001-2016
  • Table 13-6: Rubella-Number of Reported Cases, 2001-2016
  • Table 13-7: Rubella (CRS)-Number of Reported Cases, 2001-2016
  • Table 13-8: Diphtheria-Number of Reported Cases, 2001-2016
  • Table 13-9: Tetanus (Neonatal)-Number of Reported Cases, 2001-2016
  • Table 13-10: Tetanus (Total)-Number of Reported Cases, 2001-2016
  • Table 13-11: Pertussis-Number of Reported Cases, 2001-2016
  • Table 13-12: Polio-Number of Reported Cases, 2001-2016
  • Table 13-13: Yellow Fever-Number of Reported Cases, 2001-2016
  • Table 13-14: Japanese Encephalitis-Number of Reported Cases Reported, 2006-2016
  • Table 15-1: Merck Vaccine Product Pipeline
  • Table 15-2: Sanofi Vaccine Product Pipeline
  • Table 15-3: Pfizer Vaccine Product Pipeline
  • Table 16-1: Vaccine Mergers & Acquisitions
  • Table 18-1: United States Immunization Schedule
  • Table 18-2: Afghanistan Immunization Schedule
  • Table 18-3: Norway Immunization Schedule
  • Table 18-4: India Immunization Schedule
  • Table 18-5: Vietnam Immunization Schedule
  • Table 18-6: Worldwide-Total Future Deaths Averted through Vaccination (Million), 2011-2020
  • Table 18-7: Goal-Level Indicators, 2015 & 2020
  • Table 18-8: Improvement Strategies or Requirements-the Joint Commission and the Project's Collaborating Organizations
Back to Top